Delving into the Latest Updates on Shanghai Fengxian District Central Hospital with Synapse

Overview

The Efficacy and Safety of Zanubrutinib, Rituximab and Lenalidomide (ZR2) Versus Rituximab Combined With Low-dose CHOP (R-miniCHOP) in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years: A Multicenter, Prospective, Randomized, Open-label, Controlled Trial

A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of zanubrutinib, rituximab and lenalidomide (ZR2) versus rituximab combined with low-dose CHOP (R-miniCHOP) in the treatment of unfit or frail de novo diffuse large B-cell lymphoma patients aged older than or equal to 70 years

Start Date02 Mar 2022

Sponsor / Collaborator

Ruijin Hospital

[+20]

NCT05180851

/ Unknown statusEarly Phase 1IIT

Safety and Efficacy of Recombinant L-IFN Adenovirus Injection in Relapsed/Refractory Solid Tumors: a Single/Multicenter, Dose-increasing, Cohort Extension Clinical Study

This is an open-label, dose escalation study of the safety and tolerability of Recombinant oncolytic adenovirus L-IFN injection（YSCH-01） when administered via intratumoral injection in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of Recombinant L-IFN adenovirus injectionand to determine the recommended phase 1 dose for further study. The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of Recombinant L-IFN adenovirus injection

Start Date30 Nov 2021

Sponsor / Collaborator

Shanghai Fengxian District Central Hospital

[+1]

100 Clinical Results associated with Shanghai Fengxian District Central Hospital

Login to view more data

0 Patents (Medical) associated with Shanghai Fengxian District Central Hospital

Login to view more data

216

Literatures (Medical) associated with Shanghai Fengxian District Central Hospital

01 Apr 2025·Experimental Cell Research

PRC1 promotes ovarian cancer progression by binding to RPL4 and increasing MDM2-mediated p53 ubiquitination

Article

Author: Zhang, Cancan ; Zhu, Pengfeng ; Zhang, Rong ; Xu, Jiaxing ; Xu, Kai ; Wang, Fengmian ; Xu, Yinyin

Ovarian cancer (OC) is one of the most fatal gynecological carcinomas, causing significant detriment to women's health. Protein regulator of cytokinesis 1 (PRC1) is a microtubule-associated protein that is found to be highly expressed in many different cancers. Despite this, the exact way in which PRC1 stimulates the growth of OC has yet to be completely understood. Our research demonstrated that PRC1 expression was increased in OC, which was closely related to poor prognosis. Moreover, PRC1 exhibited noteworthy efficacy in enhancing the proliferation and migration capacities of OC cells, as well as affecting the cell cycle in OC cells. Silencing PRC1 significantly suppressed OC growth in vivo. Mechanically, PRC1 could interact with RPL4, which caused a decrease in RPL4/MDM2 complex formation, resulting in the enhanced ubiquitination of p53 and a reduction of p53 proteins. These findings revealed that PRC1 was involved in the RPL4-MDM2-p53 pathway thus playing a tumorigenic role on OC.

01 Apr 2025·Diabetes Care

Comment on Maddaloni et al. Bone-Vascular Axis Biomarkers: Enhancing Cardiovascular Risk Management in Type 2 Diabetes

Letter

Author: Wu, Lingling ; Guo, Meixiang ; Zhao, Kun

20 Mar 2025·Oxford Medical Case Reports

Deciphering the challenge: rhabdomyolysis diagnosis in food-dependent exercise-induced anaphylaxis

Article

Author: Zhang, Jiahua ; Wu, Jieqiong ; Tang, Tianci ; Zhang, Ye

AbstractFood-dependent exercise-induced allergies are a specific type of food allergy. However, in some cases, allergies may appear along with other diseases. Patients with allergies and concomitant rhabdomyolysis have rarely been reported. Herein, we report a 30-year-old male patient with rhabdomyolysis and no prior history of food-dependent exercise-induced allergy, and discuss our management approach. The aim of this report is to provide new insights into the diagnosis of this condition and assist clinicians in its identification.

100 Deals associated with Shanghai Fengxian District Central Hospital

Login to view more data

100 Translational Medicine associated with Shanghai Fengxian District Central Hospital

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data